These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33181159)

  • 61. Explanatory Analysis of a Machine Learning Model to Identify Hypertrophic Cardiomyopathy Patients from EHR Using Diagnostic Codes.
    Farahani NZ; Arunachalam SP; Sundaram DSB; Pasupathy K; Enayati M; Arruda-Olson AM
    Proceedings (IEEE Int Conf Bioinformatics Biomed); 2020 Dec; 2020():1932-1937. PubMed ID: 34316386
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Programmed ventricular stimulation predicts arrhythmic events and survival in hypertrophic cardiomyopathy.
    Gatzoulis KA; Georgopoulos S; Antoniou CK; Anastasakis A; Dilaveris P; Arsenos P; Sideris S; Tsiachris D; Archontakis S; Sotiropoulos E; Theopistou A; Skiadas I; Kallikazaros I; Stefanadis C; Tousoulis D
    Int J Cardiol; 2018 Mar; 254():175-181. PubMed ID: 29407088
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rapid Device-Detected Nonsustained Ventricular Tachycardia in the Risk Stratification of Hypertrophic Cardiomyopathy.
    Viswanathan K; Suszko AM; DAS M; Jackson N; Gollob M; Cameron D; Spears D; Woo A; Rakowski H; Khurana M; Chauhan VS
    Pacing Clin Electrophysiol; 2016 Jul; 39(7):642-51. PubMed ID: 27027856
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy.
    Kubo T; Kitaoka H; Yamanaka S; Hirota T; Baba Y; Hayashi K; Iiyama T; Kumagai N; Tanioka K; Yamasaki N; Matsumura Y; Furuno T; Sugiura T; Doi YL
    J Am Coll Cardiol; 2013 Oct; 62(14):1252-1259. PubMed ID: 23623916
    [TBL] [Abstract][Full Text] [Related]  

  • 66. QT spatial dispersion and sudden cardiac death in hypertrophic cardiomyopathy: Time for reappraisal.
    Magrì D; Santolamazza C; Limite L; Mastromarino V; Casenghi M; Orlando P; Pagannone E; Musumeci MB; Maruotti A; Ricotta A; Oliviero G; Piccirillo G; Volpe M; Autore C
    J Cardiol; 2017 Oct; 70(4):310-315. PubMed ID: 28341542
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
    Green JJ; Berger JS; Kramer CM; Salerno M
    JACC Cardiovasc Imaging; 2012 Apr; 5(4):370-7. PubMed ID: 22498326
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Automated extraction of sudden cardiac death risk factors in hypertrophic cardiomyopathy patients by natural language processing.
    Moon S; Liu S; Scott CG; Samudrala S; Abidian MM; Geske JB; Noseworthy PA; Shellum JL; Chaudhry R; Ommen SR; Nishimura RA; Liu H; Arruda-Olson AM
    Int J Med Inform; 2019 Aug; 128():32-38. PubMed ID: 31160009
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prognostic value of heart rate variability in patients with hypertrophic cardiomyopathy.
    Kawasaki T; Azuma A; Sakatani T; Hadase M; Kamitani T; Kawasaki S; Kuribayashi T; Sugihara H
    J Electrocardiol; 2003 Oct; 36(4):333-8. PubMed ID: 14661170
    [TBL] [Abstract][Full Text] [Related]  

  • 70. High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device.
    Wilke I; Witzel K; Münch J; Pecha S; Blankenberg S; Reichenspurner H; Willems S; Patten M; Aydin A
    J Cardiovasc Electrophysiol; 2016 Jul; 27(7):779-84. PubMed ID: 27060297
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population.
    Maron BJ; Olivotto I; Spirito P; Casey SA; Bellone P; Gohman TE; Graham KJ; Burton DA; Cecchi F
    Circulation; 2000 Aug; 102(8):858-64. PubMed ID: 10952953
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cardiac magnetic resonance imaging findings predict major adverse events in apical hypertrophic cardiomyopathy.
    Hanneman K; Crean AM; Williams L; Moshonov H; James S; Jiménez-Juan L; Gruner C; Sparrow P; Rakowski H; Nguyen ET
    J Thorac Imaging; 2014 Nov; 29(6):331-9. PubMed ID: 25314027
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients.
    Hu DJ; Xu J; Du W; Zhang JX; Zhong M; Zhou YN
    Int J Cardiovasc Imaging; 2016 Dec; 32(12):1725-1733. PubMed ID: 27566192
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Myocardial tissue characterization by gadolinium-enhanced cardiac magnetic resonance imaging for risk stratification of adverse events in hypertrophic cardiomyopathy.
    Raiker N; Vullaganti S; Collins JD; Allen BD; Choudhury L
    Int J Cardiovasc Imaging; 2020 Jun; 36(6):1147-1156. PubMed ID: 32166506
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Assessment of the association between the presence of fragmented QRS and the predicted risk score of sudden cardiac death at 5 years in patients with hypertrophic cardiomyopathy.
    Özyılmaz S; Akgül Ö; Uyarel H; Pusuroğlu H; Karayakalı M; Gül M; Çetin M; Satılmışoğlu H; Yıldırım A; Bakır İ
    Anatol J Cardiol; 2017 Jul; 18(1):54-61. PubMed ID: 28559533
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy.
    Gastl M; Gruner C; Labucay K; Gotschy A; Von Spiczak J; Polacin M; Boenner F; Kelm M; Ruschitzka F; Alkadhi H; Kozerke S; Manka R
    Open Heart; 2020; 7(1):e001152. PubMed ID: 32201584
    [TBL] [Abstract][Full Text] [Related]  

  • 77. E/e' ratio and outcome prediction in hypertrophic cardiomyopathy: the influence of outflow tract obstruction.
    Lu DY; Haileselassie B; Ventoulis I; Liu HY; Liang HY; Pozios I; Canepa M; Phillip S; Abraham MR; Abraham T
    Eur Heart J Cardiovasc Imaging; 2018 Jan; 19(1):101-107. PubMed ID: 28977350
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records.
    Pujades-Rodriguez M; Guttmann OP; Gonzalez-Izquierdo A; Duyx B; O'Mahony C; Elliott P; Hemingway H
    PLoS One; 2018; 13(1):e0191214. PubMed ID: 29324812
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy.
    Magri D; Agostoni P; Sinagra G; Re F; Correale M; Limongelli G; Zachara E; Mastromarino V; Santolamazza C; Casenghi M; Pacileo G; Valente F; Morosin M; Musumeci B; Pagannone E; Maruotti A; Uguccioni M; Volpe M; Autore C
    Int J Cardiol; 2018 Nov; 271():125-131. PubMed ID: 30087038
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Exercise hemodynamics in hypertrophic cardiomyopathy identify risk of incident heart failure but not ventricular arrhythmias or sudden cardiac death.
    Smith ED; Tome J; Mcgrath R; Kumar S; Concannon M; Day SM; Saberi S; Helms AS
    Int J Cardiol; 2019 Jan; 274():226-231. PubMed ID: 30075967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.